RxDoctor Payments Data

Ann Way

Adult Health · New Hyde Park, NYNPI 1811432982

Payments from drug & device makers

$1,159in general payments, 2019–2025

Across 10 payments — averaging $115.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$271
  • Novartis$185
  • Dova Pharmaceuticals$150
  • Sanofi$125
  • CTI Biopharma Corp.$125
  • Pharmaessentia USA Corporation$121
  • plus $182 from 3 others

What the payments were for

  • Consulting fees$18516%
  • Food & beverage$91279%
  • Education$625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,159 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$4,494
Medicare patients
39
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib65$1,043,559
BrukinsaZanubrutinib42$615,601
Ferriprox (2 Times A Day)Deferiprone19$491,785
CalquenceAcalabrutinib Maleate29$451,291
PomalystPomalidomide12$318,760
JaypircaPirtobrutinib14$310,108
Lenalidomide15$241,383
PegasysPeginterferon Alfa-2a13$62,974
Imatinib Mesylate20$47,750
Deferasirox23$15,007
EliquisApixaban11$12,903
Enoxaparin Sodium15$4,838
Hydroxyurea14$626
Acyclovir49$545
Prednisone37$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCJaypirca$62$310,10814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →